Results 151 to 160 of about 949 (170)

Varespladib Inhibits Secretory Phospholipase A2 in Bronchoalveolar Lavage of Different Types of Neonatal Lung Injury

The Journal of Clinical Pharmacology, 2011
Secretory phospholipase A2 (sPLA2), which links surfactant catabolism and lung inflammation, is associated with lung stiffness, surfactant dysfunction, and degree of respiratory support in acute respiratory distress syndrome and in some forms of neonatal lung injury. Varespladib potently inhibits sPLA2 in animal models.
Danièle De Luca, Angelo Minucci, Joaquim Trias, Domenico Tripodi, Giorgio Conti, Cecilia Zuppi, Ettore Capoluongo   +6 more
openalex   +6 more sources

Varespladib (A-002), a Secretory Phospholipase A2 Inhibitor, Reduces Atherosclerosis and Aneurysm Formation in ApoE− / − Mice

Journal of Cardiovascular Pharmacology, 2009
The family of secretory phospholipase A2 (sPLA2) enzymes has been associated with inflammatory diseases and tissue injury including atherosclerosis. A-001 is a novel inhibitor of sPLA2 enzymes discovered by structure-based drug design, and A-002 is the orally bioavailable prodrug currently in clinical development.
Heather Fraser, Colin Hislop, Robert Christie, Heather L Rick, Charles A. Reidy, Michael Chouinard, Patrick I. Eacho, Kenneth E. Gould, Joaquim Trias   +8 more
openalex   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

After FRANCIS: Next Steps in the Clinical Evaluation of Varespladib Methyl

Future Cardiology, 2010
Secretory phospholipase A(2) (sPLA(2)) represents a family of isoenzymes that participate in lipoprotein and inflammatory pathways, mediate atherosclerosis and enhance myocardial ischemic injury. The Fewer Recurrent Acute Coronary Events with Near-term Cardiovascular Inflammatory Suppression (FRANCIS) trial (NCT00743925) was a Phase II trial designed ...
openaire   +2 more sources

Varespladib (LY315920) rescues mice from rapidly lethal doses of venoms from five vipers, suggesting direct and indirect mechanisms for its therapeutic effect in a mouse model of snakebite envenomation

Toxicon, 2019
M. Lewin, Tommaso C Bulfone
semanticscholar   +2 more sources

Cystal structure of Myotoxin II from Bothrops moojeni co-crystallized with Varespladib (LY315920)

, 2019
The World Health Organization recently listed snakebite envenoming as a Neglected Tropical Disease, proposing strategies to significantly reduce the global burden of this complex pathology by 2030.
Guilherme H. M. Salvador, A. A. Gomes, Wendy Bryan-Quirós, Julián Fernández, M. Lewin, J. Gutiérrez, B. Lomonte, M. Fontes   +7 more
semanticscholar   +1 more source

Effect of the phospholipase A2 inhibitor Varespladib, and its synergism with crotalic antivenom, on the neuromuscular blockade induced by Crotalus durissus terrificus venom (with and without crotamine) in mouse neuromuscular preparations.

Toxicon, 2022
Jocimar de Souza, I. C. Oliveira, E. H. Yoshida, Nathalia M. Cantuária, J. Cogo, Kristian A. Torres-Bonilla, S. Hyslop, Nelson J. Silva Junior, R. S. Floriano, J. Gutiérrez, Y. Oshima-Franco   +10 more
semanticscholar   +1 more source

Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease.

IDrugs : the investigational drugs journal, 2009
Varespladib methyl is an oral secretory phospholipase A2 inhibitor that is being developed by Anthera Pharmaceuticals Inc for the potential treatment of coronary artery disease, acute coronary syndrome and inflammation. Varespladib methyl is a prodrug that is rapidly metabolized to varespladib, and both compounds are able to potently inhibit the ...
Mahir Karakas, Wolfgang Köenig
openalex   +2 more sources

Adverse Effects Associated with Varespladib in the VISTA-16 Trial

MD Conference Express, 2013
S. J. Nicholls, M. Cunningham
openaire   +2 more sources

The BRAVO Clinical Study Protocol: Oral Varespladib for Inhibition of Secretory Phospholipase A2 in the Treatment of Snakebite Envenoming

Toxins, 2023
Rebecca W Carter, Peter Akpunonu, Matthew R Lewin   +2 more
exaly  

Varespladib (LY315920) rescued mice from fatal neurotoxicity caused by venoms of five major Asiatic kraits (Bungarus spp.) in an experimental envenoming and rescue model

Acta Tropica, 2022
Choo Hock Tan, Kae Yi Tan
exaly